| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Green, HK, et al.
(författare)
-
Challenges with Disaster Mortality Data and Measuring Progress Towards the Implementation of the Sendai Framework
- 2019
-
Ingår i: INTERNATIONAL JOURNAL OF DISASTER RISK SCIENCE. - : Springer Science and Business Media LLC. - 2095-0055 .- 2192-6395. ; 10:4, s. 449-461
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- Disasters exact a heavy toll globally. However, the degree to which we can accurately quantify their impact, in particular mortality, remains challenging. It is critical to ensure that disaster data reliably reflects the scale, type, and distribution of disaster impacts given the role of data in: (1) risk assessments; (2) developing disaster risk management programs; (3) determining the resources for response to emergencies; (4) the types of action undertaken in planning for prevention and preparedness; and (5) identifying research gaps. The Sendai Framework for Disaster Risk Reduction 2015–2030s seven global disaster-impact reduction targets represent the first international attempt to systematically measure the effectiveness of disaster-impact reduction as a means of better informing policy with evidence. Target A of the Sendai Framework aims to “substantially reduce global disaster mortality by 2030, aiming to lower the average per 100,000 global mortality rate in the decade 2020–2030 compared to the period 2005–2015.” This article provides an overview of the complexities associated with defining, reporting, and interpreting disaster mortality data used for gauging success in meeting Target A, acknowledging different challenges for different types of hazard events and subsequent disasters. It concludes with suggestions of how to address these challenges to inform the public health utility of monitoring through the Sendai Framework.
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
- Kamstrup, P, et al.
(författare)
-
Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population
- 2022
-
Ingår i: Biomedicines. - : MDPI AG. - 2227-9059. ; 10:8
-
Tidskriftsartikel (refereegranskat)abstract
- Cardiovascular diseases are common in patients with chronic obstructive pulmonary disease (COPD). Clot formation and resolution secondary to systemic inflammation may be a part of the explanation. The aim was to determine whether biomarkers of clot formation (products of von Willebrand Factor formation and activation) and clot resolution (product of fibrin degeneration) during COPD exacerbation predicted major cardiovascular events (MACE). The cohort was based on clinical data and biobank plasma samples from a trial including patients admitted with an acute exacerbation of COPD (CORTICO-COP). Neo-epitope biomarkers of formation and the activation of von Willebrand factor (VWF-N and V-WFA, respectively) and cross-linked fibrin degradation (X-FIB) were assessed using ELISAs in EDTA plasma at the time of acute admission, and analyzed for time-to-first MACE within 36 months, using multivariable Cox proportional hazards models. In total, 299/318 participants had samples available for analysis. The risk of MACE for patients in the upper quartile of each biomarker versus the lower quartile was: X-FIB: HR 0.98 (95% CI 0.65–1.48), VWF-N: HR 1.56 (95% CI 1.07–2.27), and VWF-A: HR 0.78 (95% CI 0.52–1.16). Thus, in COPD patients with an acute exacerbation, VWF-N was associated with future MACE and warrants further studies in a larger population.
|
|
| 10. |
|
|
